The software will allow laboratories to generate custom expert rules, which can guide laboratory and clinical action upon receipt of results from both systems.
Magellan’s VersaTREK automated microbial-detection system offers four tests on one system, including detection of bacteria in blood culture and sterile body fluids as well as mycobacteria detection and M. tuberculosis susceptibility testing.
Bruker‘s MALDI Biotyper solution enables molecular identification, taxonomical classification or dereplication of microorganisms like bacteria, yeasts and fungi.
The MALDI Biotyper is available in a clinical version with an IVD-CE mark in the European community, and is labeled research-use-only in the US.
Bruker plans to seek US FDA clearance, and regulatory clearance is underway in several other countries.
The Sensititre product line features both EU and US clearances, while Japan clearance for the Sensititre system is in process.
Magellan’s US microbiology sales force will then promote the complementary product offerings.
Magellan president and CEO Hiroshi Uchida said they can soon combine the MALDI Biotyper’s rapid identification of more than 2,000 species of bacteria, as well as yeast and fungi, with Sensititre’s true MIC results for an expansive list of antimicrobial drugs and dilution ranges, enabling physicians to make more-precise dosing decisions.
